Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$118.13 USD
+0.50 (0.43%)
Updated Sep 17, 2024 04:01 PM ET
After-Market: $118.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.13 USD
+0.50 (0.43%)
Updated Sep 17, 2024 04:01 PM ET
After-Market: $118.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
Zacks News
3 Medical Product Stocks Likely to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Abbott (ABT) Meets Q3 Earnings Estimates, Lowers EPS Guidance
by Zacks Equity Research
We are optimistic about Abbott's (ABT) strong and consistent EPD and Medical Devices performance organically.
Abbott (ABT) Meets Q3 Earnings Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0.00% and -0.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.
Abbott Forms Alliance With Omada Health for Diabetes Care
by Zacks Equity Research
Abbott (ABT) collaborates with Omada Health to revolutionize diabetes care by expanding technological access.
Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $79.62, moving -0.65% from the previous trading session.
Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics (AXNX) Upbeat on Results of Its ARTISAN-SNM Study
by Zacks Equity Research
Axonics (AXNX) expects to improve performance on the positive outcome of the study.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $81.97, moving +1.11% from the previous trading session.
Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test
by Zacks Equity Research
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT
by Zacks Equity Research
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.
Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System
by Zacks Equity Research
Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.
Abbott (ABT) Stock Moves -0.24%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $82.66 in the latest trading session, marking a -0.24% move from the prior day.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Abbott Receives European Nod for Pediatric Heart Devices
by Zacks Equity Research
Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.
Abbott Partners With Sanofi to Upgrade Diabetes Management
by Zacks Equity Research
Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $83.36 in the latest trading session, marking a -1.08% move from the prior day.
Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement
by Zacks Equity Research
With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.
Abbott Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Abbott Laboratories has been struggling lately, but the selling pressure may be coming to an end soon.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $83.19, marking a -1.22% move from the previous day.
Abbott (ABT) Launches Pivotal Trial TRILUMINATE in the US
by Zacks Equity Research
Given the lack of an alternative therapy to replace tricuspid regurgitation surgery, Abbott (ABT) should be at an advantage in this space.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
5 Cancer-Fighting Stocks to Add to Your Portfolio
by Zacks Equity Research
Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $84.22, moving +0.68% from the previous trading session.